All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

July 20th 2022

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the OVAL trial.

CB-010 Exhibits Impressive Early Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

July 20th 2022

The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.

ADCs Begin to Carve a Place in the Treatment Landscape for Ovarian Cancer

July 20th 2022

Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates represent a promising development for this population.

Polatuzumab Vedotin Plus R-CHP Significantly Extends PFS in Untreated DLBCL

July 19th 2022

Polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, induced a 27% reduction in relative risk for disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

Real-World Evidence On Shared Decision-Making Is Critical for Improving Patient Satisfaction in DLBCL

July 19th 2022

Integrating the lived experiences of patients with relapsed or refractory diffuse-large B-cell lymphoma into treatment-decision making should be a priority for practicing oncologists.

Pirtobrutinib Elicits 50% Response Rate in BTK-Pretreated MCL

July 19th 2022

Pirtobrutinib demonstrated potent antitumor activity and a low incidence of adverse effects in patients with BTK-pretreated and -naïve mantle cell lymphoma.

Zanubrutinib Represents Viable Treatment Option for Acalabrutinib-Intolerant B-cell Malignancies

July 19th 2022

Treatment with zanubrutinib maintained or improved response without an increase in acalabrutinib intolerance events in patients with previously treated B-cell malignancies.

CHOP-Based Combinations Represent Evolving Standard of Care in Frontline Treatment of PTCL

July 19th 2022

Neha Mehta-Shah, MD, MSCI, discusses frontline therapies in peripheral T-cell lymphoma, highlighting the current treatment landscape and the need to explore more treatment options in clinical trials.

Trastuzumab Deruxtecan Approved in Europe for HER2+ Metastatic Breast Cancer Treated With 1 or More Prior Anti–HER2-Based Regimens

July 19th 2022

The European Commission has approved fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received at least 1 anti–HER2-based regimen.

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

July 19th 2022

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

BTK Inhibitor–Based Combinations May Improve the Efficacy of SOC Treatment in CNS Lymphoma

July 19th 2022

Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.

Sesen Bio Pauses Clinical Development for Vicineum in BCG-Unresponsive NMIBC

July 18th 2022

The clinical development of Vicineum for use as a potential therapeutic option in patients with high-risk, Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Pralsetinib Approved for RET Fusion+ Metastatic NSCLC in Hong Kong, China

July 18th 2022

Pralsetinib has been approved in Hong Kong, China, for use in treatment-naïve and pretreated adult patients with RET fusion–positive, metastatic non–small cell lung cancer.

Kim and Schwartz Break Down the Role of Radiation Segmentectomy With Y-90 in Early-Stage HCC

July 18th 2022

Edward Kim, MD, and Myron E. Schwartz, MD, discuss the background and findings of the RASER study, the role of radiation segmentectomy, and its potential to be combined with immunotherapy.

Alpelisib/Fulvestrant Combination Wins Philippine Approval for PIK3CA-Mutated, HR+/HER2– Metastatic Breast Cancer

July 18th 2022

The Philippine FDA has granted approval to alpelisib in combination with fulvestrant for the treatment of patients with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

Streamlined Genomic Testing Platforms Are Taking on A Bigger Role in Cancer Care

July 18th 2022

Genetic testing has afforded oncologists with the opportunity to identify patients who may have a higher risk of developing cancer and identify actionable mutations to allow patients to receive targeted therapy and have their long-term treatment plan mapped out at diagnosis.

Europe Validates Marketing Application for Trastuzumab Duocarmazine for Metastatic HER2+ Breast Cancer

July 18th 2022

The European Medicines Agency has validated the marketing authorization application for trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic breast cancer.

Alexander Philipovskiy MD, PhD joins Florida Cancer Specialists Drug Development Unit in Lake Mary Florida

July 18th 2022

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome Alexander Philipovskiy, MD, PhD, as a principal investigator at the Florida Cancer Specialists & Research Institute Drug Development Unit.

Is It Time to Formally Recognize That PFS Is More Than a "Surrogate" End Point?

July 18th 2022

Peer-reviewed articles continue to challenge the recognition of progression-free survival as an acceptable primary end point in randomized cancer trials or insist on labeling this objectively measured outcome as nothing more than a potential surrogate for effects representing actual clinically meaningful results.

Optimized Therapy Requires More Than Binary Understanding of HER2 Positivity in Metastatic Breast Cancer

July 16th 2022

Neratinib-based combinations, antibody-drug conjugates, and bispecific antibodies represent novel and effective treatment options for patients with pretreated HER2-mutant and HER2-low metastatic breast cancer, but the successful integration of these regimens into care will require further investigation into current definitions of HER2 positivity.